Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - olanzapine, quantity: 7.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; magnesium stearate; hypromellose; hyprolose; titanium dioxide; polysorbate 80; macrogol 400 - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses. ,olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - doxorubicin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - doxorubicin hydrochloride -

United States - English - NLM (National Library of Medicine)

accord healthcare inc. - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy  for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. tacrolimus ointment is not indicated for children younger than 2 years of age (see boxed warning, warnings and precautions: pediatric use). tacrolimus ointment is contraindicated in patients with a history of hypersensitivity to tacrolimus or any other component of the ointment.

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - capecitabine - colonic neoplasms; breast neoplasms; colorectal neoplasms; stomach neoplasms - antineoplastic agents - capecitabine accord is indicated for the adjuvant treatment of patients following surgery of stage-iii (dukes’ stage-c) colon cancer.capecitabine accord is indicated for the treatment of metastatic colorectal cancer.capecitabine accord is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.capecitabine accord in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.capecitabine accord is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

United States - English - NLM (National Library of Medicine)

accord healthcare inc. - capecitabine (unii: 6804dj8z9u) (capecitabine - unii:6804dj8z9u) - capecitabine 500 mg - capecitabine tablets are indicated for the: - adjuvant treatment of patients with stage iii colon cancer as a single agent or as a component of a combination chemotherapy regimen. - perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. - treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. capecitabine tablets are indicated for the: - treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. - treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. capecitabine tablets are indicated for the: - treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. - treatment of adults with her2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. capecitabine tablets are indicated for the adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. capecitabine is contraindicated in patients with history of severe hypersensitivity reaction to fluorouracil or capecitabine [see adverse reactions (6.1)]. risk summary based on findings in animal reproduction studies and its mechanism of action [see clinical pharmacology (12.1)], capecitabine can cause fetal harm when administered to a pregnant woman. available human data with capecitabine use in pregnant women is not sufficient to inform the drug-associated risk. in animal reproduction studies, administration of capecitabine to pregnant animals during the period of organogenesis caused embryolethality and teratogenicity in mice and embryolethality in monkeys at 0.2 and 0.6 times the exposure (auc) in patients receiving the recommended dose of 1,250 mg/m 2 twice daily, respectively (see data). advise pregnant women of the potential risk to a fetus. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data oral administration of capecitabine to pregnant mice during the period of organogenesis at a dose of 198 mg/kg/day caused malformations and embryo lethality. in separate pharmacokinetic studies, this dose in mice produced 5’-dfur auc values that were approximately 0.2 times the auc values in patients administered the recommended daily dose. malformations in mice included cleft palate, anophthalmia, microphthalmia, oligodactyly, polydactyly, syndactyly, kinky tail and dilation of cerebral ventricles. oral administration of capecitabine to pregnant monkeys during the period of organogenesis at a dose of 90 mg/kg/day, caused fetal lethality. this dose produced 5’-dfur auc values that were approximately 0.6 times the auc values in patients administered the recommended daily dose. risk summary there is no information regarding the presence of capecitabine or its metabolites in human milk, or on its effects on milk production or the breastfed child. capecitabine metabolites were present in the milk of lactating mice (see data) . because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with capecitabine and for 1 week after the last dose. data lactating mice given a single oral dose of capecitabine excreted significant amounts of capecitabine metabolites into the milk. capecitabine can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)]. pregnancy testing verify pregnancy status in females of reproductive potential prior to initiating capecitabine. contraception females advise females of reproductive potential to use effective contraception during treatment with capecitabine and for 6 months after the last dose. males based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with capecitabine and for 3 months after the last dose [see nonclinical toxicology (13.1)]. infertility based on animal studies, capecitabine may impair fertility in females and males of reproductive potential [see nonclinical toxicology (13.1)]. the safety and effectiveness of capecitabine in pediatric patients have not been established. safety and effectiveness were assessed, but not established in two single arm studies in 56 pediatric patients aged 3 months to < 17 years with newly diagnosed gliomas. in both trials, pediatric patients received an investigational pediatric formulation of capecitabine concomitantly with and following completion of radiation therapy (total dose of 5580 cgy in 180 cgy fractions). the relative bioavailability of the investigational formulation to capecitabine was similar. the adverse reaction profile was consistent with that of adults, with the exception of laboratory abnormalities which occurred more commonly in pediatric patients. the most frequently reported laboratory abnormalities (per-patient incidence ≥ 40%) were increased alt (75%), lymphocytopenia (73%), hypokalemia (68%), thrombocytopenia (57%), hypoalbuminemia (55%), neutropenia (50%), low hematocrit (50%), hypocalcemia (48%), hypophosphatemia (45%) and hyponatremia (45%). of 7938 patients with colorectal cancer who were treated with capecitabine, 33% were older than 65 years. of the 4536 patients with metastatic breast cancer who were treated with capecitabine, 18% were older than 65 years. of 1951 patients with gastric, esophageal, or gastrointestinal junction cancer who were treated with capecitabine, 26% were older than 65 years. of 364 patients with pancreatic cancer who received adjuvant treatment with capecitabine, 47% were 65 years or older. no overall differences in efficacy were observed comparing older versus younger patients with colorectal cancer, gastric, esophageal or gastrointestinal junction cancer, or pancreatic cancer using the approved recommended dosages and treatment regimens. older patients experience increased gastrointestinal toxicity due to capecitabine compared to younger patients. deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil [see drug interactions (7.1)]. the exposure of capecitabine and its inactive metabolites (5-dfur and fbal) increases in patients with clcr < 50 ml/min as determined by cockcroft-gault [see clinical pharmacology (12.3)]. reduce the dosage for patients with clcr of 30 to 50 ml/min [see dosage and administration (2.6)]. there is limited experience with capecitabine in patients with clcr < 30 ml/min, and a dosage has not been established in those patients. if no treatment alternative exists, capecitabine could be administered to such patients on an individual basis applying a reduced starting dose, close monitoring of a patient's clinical and biochemical data and dose modifications guided by observed adverse reactions. the exposure of capecitabine increases in patients with mild to moderate hepatic impairment. the effect of severe hepatic impairment on the safety and pharmacokinetics of capecitabine is unknown [ see clinical pharmacology (12.3)]. monitor patients with hepatic impairment more frequently for adverse reactions.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - temozolomide, quantity: 250 mg - capsule, hard - excipient ingredients: gelatin; colloidal anhydrous silica; sodium starch glycollate; tartaric acid; stearic acid; lactose; purified water; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - temozolomide, quantity: 180 mg - capsule, hard - excipient ingredients: purified water; lactose; titanium dioxide; colloidal anhydrous silica; iron oxide yellow; gelatin; tartaric acid; stearic acid; sodium starch glycollate; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - temozolomide, quantity: 140 mg - capsule, hard - excipient ingredients: gelatin; purified water; indigo carmine; colloidal anhydrous silica; stearic acid; titanium dioxide; tartaric acid; sodium starch glycollate; lactose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - temozolomide, quantity: 100 mg - capsule, hard - excipient ingredients: titanium dioxide; colloidal anhydrous silica; stearic acid; gelatin; tartaric acid; iron oxide red; purified water; sodium starch glycollate; lactose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.